Go Pro
→ Iran War Shock: What I Was Told In That Private Meeting (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioCardia, Inc. stock logo
BCDA
BioCardia
$1.15
$0.98
$0.75
▼
$2.29
$17.41M0.49266,697 shs158,989 shs
Enzon Pharmaceuticals Inc. stock logo
ENZN
Enzon Pharmaceuticals
$4.35
$4.49
$1.50
▼
$9.50
$3.23M-0.051,513 shsN/A
LIFE
Ethos Technologies Inc. Class A Common Stock
$38.64
$24.74
$9.45
▼
$40.97
$2.46BN/A1.82 million shs1.09 million shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioCardia, Inc. stock logo
BCDA
BioCardia
0.00%+13.86%+39.53%+25.00%-41.83%
Enzon Pharmaceuticals Inc. stock logo
ENZN
Enzon Pharmaceuticals
0.00%0.00%0.00%-27.50%-51.67%
LIFE
Ethos Technologies Inc. Class A Common Stock
0.00%+13.11%+89.23%+104.66%+3,863,999,900.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioCardia, Inc. stock logo
BCDA
BioCardia
$1.15
$0.98
$0.75
▼
$2.29
$17.41M0.49266,697 shs158,989 shs
Enzon Pharmaceuticals Inc. stock logo
ENZN
Enzon Pharmaceuticals
$4.35
$4.49
$1.50
▼
$9.50
$3.23M-0.051,513 shsN/A
LIFE
Ethos Technologies Inc. Class A Common Stock
$38.64
$24.74
$9.45
▼
$40.97
$2.46BN/A1.82 million shs1.09 million shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioCardia, Inc. stock logo
BCDA
BioCardia
0.00%+13.86%+39.53%+25.00%-41.83%
Enzon Pharmaceuticals Inc. stock logo
ENZN
Enzon Pharmaceuticals
0.00%0.00%0.00%-27.50%-51.67%
LIFE
Ethos Technologies Inc. Class A Common Stock
0.00%+13.11%+89.23%+104.66%+3,863,999,900.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioCardia, Inc. stock logo
BCDA
BioCardia
2.00
Hold$25.002,073.91% Upside
Enzon Pharmaceuticals Inc. stock logo
ENZN
Enzon Pharmaceuticals
0.00
N/AN/AN/A
LIFE
Ethos Technologies Inc. Class A Common Stock
2.71
Moderate Buy$32.29-16.44% Downside

Current Analyst Ratings Breakdown

Latest ENZN, LIFE, and BCDA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/24/2026
BioCardia, Inc. stock logo
BCDA
BioCardia
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
8/21/2026
LIFE
Ethos Technologies Inc. Class A Common Stock
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D)
8/11/2026
BioCardia, Inc. stock logo
BCDA
BioCardia
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong Sell ➝ Hold
8/4/2026
LIFE
Ethos Technologies Inc. Class A Common Stock
William Blair logo
William Blair
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$33.00
8/4/2026
LIFE
Ethos Technologies Inc. Class A Common Stock
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Outperform
8/4/2026
LIFE
Ethos Technologies Inc. Class A Common Stock
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$35.00
8/4/2026
LIFE
Ethos Technologies Inc. Class A Common Stock
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$27.00 ➝ $33.00
8/4/2026
LIFE
Ethos Technologies Inc. Class A Common Stock
Citizens Jmp logo
Citizens Jmp
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetMarket Outperform$27.00 ➝ $33.00
8/4/2026
LIFE
Ethos Technologies Inc. Class A Common Stock
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$27.00 ➝ $37.00
8/4/2026
LIFE
Ethos Technologies Inc. Class A Common Stock
Robert W. Baird logo
Robert W. Baird
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$26.00 ➝ $32.00
7/17/2026
BioCardia, Inc. stock logo
BCDA
BioCardia
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
(Data available from 8/31/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioCardia, Inc. stock logo
BCDA
BioCardia
$60K290.18N/AN/A$0.08 per share14.38
Enzon Pharmaceuticals Inc. stock logo
ENZN
Enzon Pharmaceuticals
$30K107.59N/AN/A($3.40) per share-1.28
LIFE
Ethos Technologies Inc. Class A Common Stock
$387.61M6.36$1.22 per share31.72($0.39) per share-99.08
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioCardia, Inc. stock logo
BCDA
BioCardia
-$8.23M-$0.64N/AN/AN/AN/A-569.36%-183.15%11/11/2026 (Estimated)
Enzon Pharmaceuticals Inc. stock logo
ENZN
Enzon Pharmaceuticals
-$3.41M-$6.84N/AN/AN/AN/A-21.54%-7.22%N/A
LIFE
Ethos Technologies Inc. Class A Common Stock
$71.15M-$2.85N/A30.43N/AN/AN/AN/AN/A

Latest ENZN, LIFE, and BCDA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2026Q2 2026
BioCardia, Inc. stock logo
BCDA
BioCardia
-$0.18-$0.13+$0.05-$0.13N/AN/A
8/3/2026Q2 2026
LIFE
Ethos Technologies Inc. Class A Common Stock
$0.19$0.53+$0.34$0.30N/A$189.56 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
BioCardia, Inc. stock logo
BCDA
BioCardia
N/AN/AN/AN/AN/A
Enzon Pharmaceuticals Inc. stock logo
ENZN
Enzon Pharmaceuticals
$0.122.76%N/AN/A N/A
LIFE
Ethos Technologies Inc. Class A Common Stock
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioCardia, Inc. stock logo
BCDA
BioCardia
N/A
2.09
2.09
Enzon Pharmaceuticals Inc. stock logo
ENZN
Enzon Pharmaceuticals
0.42
2.01
1.16
LIFE
Ethos Technologies Inc. Class A Common Stock
N/A
4.18
4.18

Institutional Ownership

CompanyInstitutional Ownership
BioCardia, Inc. stock logo
BCDA
BioCardia
20.57%
Enzon Pharmaceuticals Inc. stock logo
ENZN
Enzon Pharmaceuticals
N/A
LIFE
Ethos Technologies Inc. Class A Common Stock
61.72%

Insider Ownership

CompanyInsider Ownership
BioCardia, Inc. stock logo
BCDA
BioCardia
17.40%
Enzon Pharmaceuticals Inc. stock logo
ENZN
Enzon Pharmaceuticals
0.40%
LIFE
Ethos Technologies Inc. Class A Common Stock
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
BioCardia, Inc. stock logo
BCDA
BioCardia
4015.14 million12.51 millionOptionable
Enzon Pharmaceuticals Inc. stock logo
ENZN
Enzon Pharmaceuticals
N/A742,000739,000Not Optionable
LIFE
Ethos Technologies Inc. Class A Common Stock
61463.76 millionN/AN/A

Recent News About These Companies

Ethos Technologies Inc. Class A Common Stock (NASDAQ:LIFE) Receives Average Rating of "Moderate Buy" from Brokerages
August 29 at 2:15 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30989628
Ethos Technologies Inc. Class A Common Stock (NASDAQ:LIFE) Given Consensus Recommendation of "Moderate Buy" by Analysts
August 29 at 2:13 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-ethos-technologies-inc-class-a-common-stock-nasdaq-life-given-consensus-recommendation-of-moderate-buy-by-analysts-2026-08-29/
Insider Selling: Ethos Technologies Inc. Class A Common Stock (NASDAQ:LIFE) Major Shareholder Sells $3,570,170.40 in Stock
August 24, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30980642
Insider Selling: Ethos Technologies Inc. Class A Common Stock (NASDAQ:LIFE) President Sells $3,939,305.57 in Stock
August 24, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30980632
Ethos Technologies Inc. Class A Common Stock (NASDAQ:LIFE) CAO Sells $283,625.45 in Stock
August 22, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-life-insider-buying-and-selling-2026-08-22/
Ethos Technologies Inc. Class A Common Stock (NASDAQ:LIFE) CAO Brandt Walter Kucharski Sells 8,735 Shares
August 21, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/ethos-technologies-inc-class-a-common-stock-nasdaqlife-cao-brandt-walter-kucharski-sells-8735-shares-2026-08-21/
Insider Selling: Ethos Technologies Inc. Class A Common Stock (NASDAQ:LIFE) CEO Sells 27,924 Shares of Stock
August 21, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-selling-ethos-technologies-inc-class-a-common-stock-nasdaqlife-ceo-sells-27924-shares-of-stock-2026-08-21/
Ethos Technologies Inc. Class A Common Stock (NASDAQ:LIFE) CEO Sells $954,668.00 in Stock
August 21, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/ethos-technologies-inc-class-a-common-stock-nasdaqlife-ceo-sells-95466800-in-stock-2026-08-21/
Ethos Technologies Inc. Class A Common Stock (NASDAQ:LIFE) President Lingke Wang Sells 118,333 Shares of Stock
August 21, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/ethos-technologies-inc-class-a-common-stock-nasdaqlife-president-lingke-wang-sells-118333-shares-of-stock-2026-08-21/
Insider Selling: Ethos Technologies Inc. Class A Common Stock (NASDAQ:LIFE) Major Shareholder Sells 34,821 Shares
August 21, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-selling-ethos-technologies-inc-class-a-common-stock-nasdaqlife-major-shareholder-sells-34821-shares-2026-08-21/
Ethos Technologies Inc. Class A Common Stock (NASDAQ:LIFE) Major Shareholder Us (Ttgp) Ltd. Sc Sells 107,795 Shares of Stock
August 21, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/ethos-technologies-inc-class-a-common-stock-nasdaqlife-major-shareholder-us-ttgp-ltd-sc-sells-107795-shares-of-stock-2026-08-21/
Ethos to Present at the Goldman Sachs Communacopia + Technology Conference
August 19, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/19/3347968/0/en/ethos-to-present-at-the-goldman-sachs-communacopia-technology-conference.html
Brandt Walter Kucharski Sells 5,611 Shares of Ethos Technologies Inc. Class A Common Stock (NASDAQ:LIFE) Stock
August 19, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-life-insider-buying-and-selling-2026-08-19/
Ethos Technologies Inc. Class A Common Stock (NASDAQ:LIFE) CAO Sells $192,232.86 in Stock
August 18, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/ethos-technologies-inc-class-a-common-stock-nasdaqlife-cao-sells-19223286-in-stock-2026-08-18/
Ethos Technologies Inc. Class A Common Stock (NASDAQ:LIFE) President Sells 22,623 Shares
August 18, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/ethos-technologies-inc-class-a-common-stock-nasdaqlife-president-sells-22623-shares-2026-08-18/
Ethos Technologies Inc. Class A Common Stock (NASDAQ:LIFE) CFO Christopher Capozzi Sells 26,184 Shares of Stock
August 18, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/ethos-technologies-inc-class-a-common-stock-nasdaqlife-cfo-christopher-capozzi-sells-26184-shares-of-stock-2026-08-18/
Ethos Technologies Inc. Class A Common Stock (NASDAQ:LIFE) CEO Peter George Colis Sells 29,342 Shares of Stock
August 18, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/ethos-technologies-inc-class-a-common-stock-nasdaqlife-ceo-peter-george-colis-sells-29342-shares-of-stock-2026-08-18/
Brandt Walter Kucharski Sells 77,436 Shares of Ethos Technologies Inc. Class A Common Stock (NASDAQ:LIFE) Stock
August 18, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/brandt-walter-kucharski-sells-77436-shares-of-ethos-technologies-inc-class-a-common-stock-nasdaqlife-stock-2026-08-18/
Ethos Signs Erin Andrews as Its Next Sports Partner in Growing Campaign to Make Life Insurance Accessible for Every Family
August 13, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/13/3344578/0/en/ethos-signs-erin-andrews-as-its-next-sports-partner-in-growing-campaign-to-make-life-insurance-accessible-for-every-family.html
Ethos Technologies Inc. Class A Common Stock (NASDAQ:LIFE) Upgraded by Wall Street Zen to "Hold" Rating
August 8, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/ethos-technologies-inc-class-a-common-stock-nasdaqlife-upgraded-by-wall-street-zen-to-hold-rating-2026-08-08/
Ethos Technologies advances 24% after strong results
August 5, 2026  |  seekingalpha.comhttps://seekingalpha.com/news/4624691-ethos-technologies-advances-24-after-strong-results

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Laboratory with a cryogenic quantum processor chamber, optical laser setup on a table, and data monitors displaying waveforms.
Quantum Earnings Week: Winners and Losers Are Finally Emerging
By Nathan Reiff | August 8, 2026
SpaceX logo beside a rocket on a launch pad at sunset, with a colorful sky in the background.
SpaceX’s First Earnings Report Could Decide Whether Shorts or Bulls Have Control
By Jeffrey Neal Johnson | August 3, 2026
Wooden blocks reading "Stock Buybacks" with chart and dollar icons, surrounded by stacked coins on a table.
$27 Billion in Buybacks: 3 Stocks Betting Their Strong Runs Aren’t Over
By Leo Miller | August 23, 2026
Conceptual pie chart with segments depicting industry sectors like agriculture, shipping, energy, robotics, and technology against a city skyline.
Venture Into High-Volatility Corners of the Market With These 3 ETFs
By Nathan Reiff | August 29, 2026
Printed quarterly statement with revenue chart beside a tablet showing a dividend overview chart, on a desk overlooking a city skyline.
These 5 Dividend Stocks Show Why Income Investing Still Matters
By Ryan Hasson | August 17, 2026
BioCardia stock logo

BioCardia NASDAQ:BCDA

$1.15 0.00 (0.00%)
Closing price 08/28/2026 04:00 PM Eastern
Extended Trading
$1.16 +0.01 (+0.87%)
As of 08:10 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.

Enzon Pharmaceuticals stock logo

Enzon Pharmaceuticals OTCMKTS:ENZN

$4.35 0.00 (0.00%)
As of 08/28/2026

Enzon Pharmaceuticals, Inc., together with its subsidiaries, does not have significant operations. Previously, the company marketed its patented drug product, PegIntron. It also had a marketing agreement with Micromet AG relating to the Vicineum drug; and a licensing agreement regarding SC Oncaspar and certain other drugs. The company was formerly known as Enzon, Inc and changed its name to Enzon Pharmaceuticals, Inc. in December 2002. Enzon Pharmaceuticals, Inc. was incorporated in 1981 and is headquartered in Cranford, New Jersey.

Ethos Technologies Inc. Class A Common Stock NASDAQ:LIFE

$38.64 0.00 (0.00%)
As of 08/28/2026 04:00 PM Eastern

Ethos Technologies Inc operates a technology-driven, direct-to-consumer platform for the distribution of life insurance products. Through its digital underwriting, data analytics, and proprietary technology, it enables consumers to explore, compare, and purchase life insurance policies online. The platform serves consumers, agents, and insurance carriers, and supports the application and policy issuance process through an online interface. The company works with insurance carriers to offer life insurance products in the United States through digital channels and independent agents. It generates revenue through commissions paid by carriers from policies activated and sold through its platform as well as from the provision of third-party administrator services for such policies.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas